Tilt and decentration of aberration-correcting IOLs affect VA

Article

Aberration-correcting IOLs are more sensitive to decentration and tilt

Aberration-correcting IOLs are more sensitive to decentration and tilt, according to a paper in the Journal of Cataract and Refractive Surgery.

Dr David Madrid-Costa and his team, Optics Department, University of Valencia, Valencia, Spain, completed a cohort study on 10 eyes of 10 patients. Two aspheric aberration-correcting IOLs and two spherical IOLs were tested on all patients. The outcome measures included monocular distance visual acuity at 100%, 50% and 10% and depth of focus.

After centration of the IOLs there were no differences in visual acuity between all four IOLs. However, both aberration-correcting were found to be more sensitive to tilt and decentration than the spherical IOLs.

The results demonstrated that higher residual spherical aberration slightly improved depth of focus and defocus tolerance. Visual quality in the eyes with aspheric aberration-correcting IOLs presented with corneal higher-order aberrations in those who have an average human cornea.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.